drugset / Trial / NCT05244642

A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

NCT05244642

RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, randomized, phase 3 trial to evaluate the efficacy of Penpulimab vs. standard chemotherapy selected by investigator in patients with relapsed or refractory classic Hodgkin's lymphoma.

Timeline

Start
2022-02-15
Primary completion
2025-12-30
Completion
2026-03-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carboplatin Small molecule 5 unknown
Comparator Cisplatin Other / unclassified 25 mg/m2
Comparator Cisplatin Other / unclassified 100 mg/m2
Comparator Cytarabine Small molecule 2 mg/m2
Comparator Dexamethasone Small molecule 10 mg/m2
Comparator Dexamethasone Small molecule 40 mg
Comparator Doxorubicin Other / unclassified 15 mg/m2
Comparator Etoposide Small molecule 40 mg/m2
Comparator Etoposide Small molecule 60 mg/m2
Comparator Etoposide Small molecule 65 mg/m2
Comparator Etoposide Small molecule 100 mg/m2
Comparator Gemcitabine Small molecule 800 mg/m2
Comparator Gemcitabine Small molecule 1000 mg/m2
Comparator Ifosfamide Small molecule 2 mg/m2
Comparator Ifosfamide Small molecule 5 mg/m2
Comparator Ifosfamide Small molecule 1 g/kg
Comparator Ifosfamide Small molecule 1.33 g/kg
Comparator Methylprednisolone Other / unclassified 500 mg
Comparator Mitoxantrone Small molecule 8 mg/m2
Comparator Oxaliplatin Small molecule 85 mg/m2
Comparator Oxaliplatin Small molecule 100 mg/m2
Subject Penpulimab Monoclonal antibody 200 mg Intravenous
Comparator Prednisone Other / unclassified 100 mg
Comparator Vinorelbine Small molecule 20 mg/m2

Indications